HR for 10 year all-cause and CVD mortality, by HAQ at baseline and year 1 in rheumatoid arthritis subgroup
| Predictor | n | Univariate | HAQ at baseline multivariate | HAQ at year 1 multivariate |
|---|---|---|---|---|
| Adjusted for age and sex | Adjusted for age and sex | Adjusted for age and sex | ||
| HR (95% CI) | HR (95% CI) | HR (95% CI) | ||
| ACR, American College of Rheumatology; CVD, cardiovascular disease; DAS28, Disease Activity score 28; DMARD, disease-modifying anti-rheumatic drug; HAQ, Health Assessment Questionnaire; HR, hazards ratio; RF, rheumatoid factor. | ||||
| All deaths | ||||
| HAQ at baseline (each increase of score by 1) | 698 | 1.29 (1.01 to 1.64) | 1.27 (0.90 to 1.79) | |
| HAQ at year 1 (each increase of score by 1) | 698 | 1.48 (1.19 to 1.82) | 1.48 (1.13 to 1.93) | |
| Change in HAQ from baseline to year 1 (adjusted for baseline HAQ) | ||||
| Reduction in HAQ score from baseline to year 1 | 365 | 1 | ||
| No change in HAQ score from baseline to year 1 | 99 | 1.77 (1.06 to 2.96) | ||
| Increase in HAQ score from baseline to year 1 | 234 | 1.39 (0.93 to 2.06) | ||
| Swollen and tender joint count at baseline (each increase in count by 1) | 698 | 1.01 (0.99 to 1.03) | ||
| Swollen and tender joint count at Year 1 (each increase in count by 1) | 696 | 0.99 (0.96 to 1.03) | ||
| RF positive (RF titre ⩾1:80) at baseline | 620 | 1.63 (1.1 to 2.39) | 1.84 (1.23 to 2.76) | 1.69 (1.12 to 2.54) |
| Satisfy ACR criteria at baseline | 698 | 1.13 (0.76 to 1.68) | ||
| DAS28 score at baseline (each increase of score by 1) | 552 | 1.22 (1.04 to 1.42) | 1.13 (0.94 to 1.37) | 1.12 (0.94 to 1.33) |
| Treated with DMARDs by first year | 698 | 1.40 (0.95 to 2.06) | ||
| Deaths due to CVD | ||||
| HAQ at baseline (each increase of score by 1) | 636 | 1.1 (0.78 to 1.56) | 1.15 (0.79 to 1.67) | |
| HAQ at year 1 (each increase of score by 1) | 636 | 1.53 (1.14 to 2.06) | 1.52 (1.09 to 2.12) | |
| Change in HAQ from baseline to year 1 (adjusted for baseline HAQ) | ||||
| Reduction in HAQ Score from baseline to year 1 | 334 | 1 | ||
| No change in HAQ Score from baseline to year 1 | 86 | 1.39 (0.61 to 3.13) | ||
| Increase in HAQ Score from baseline to year 1 | 216 | 1.66 (0.97 to .84) | ||
| Swollen and tender joint count at baseline (each increase in count by 1) | 636 | 0.99 (0.96 to 1.02) | ||
| Swollen and tender joint count at Year 1 (each increase in count by 1) | 634 | 0.99 (0.94 to 1.03) | ||
| RF-positive (RF titre ⩾1:80) at baseline | 570 | 2.46 (1.46 to 4.17) | 2.45 (1.45 to 4.14) | 2.30 (1.36 to 3.9) |
| Satisfy ACR criteria at baseline | 636 | 1.02 (0.59 to 1.76) | ||
| DAS28 score at baseline (each increase of score by 1) | 508 | 1.15 (0.93 to 1.41) | ||
| Treated with DMARDs by first year | 636 | 1.64 (0.95 to 2.82) | ||